|
 |
| home > pmps > spring 2003 > life cycle management - developing new dosage forms for new indications |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
New Indications for Existing Compounds
Pharmaceutical companies with drugs that are successful in the marketplace will look at all opportunities to extend the commercial life of their products. Numerous options for life cycle extension exist, including reformulation, new patents, new dosing regimes and chemical modifications. A seemingly underused option is the development of an existing compound for a new indication. The limited use of this option can be understood from the inherent risks attached to it. Many compounds which are on the market today can be applied in more than one disorder.
Well known examples include antibiotics and antiviral agents, cardiovascular drugs, antidepressants, immunosuppressants and anti-ulcer agents. The most compelling example is probably antibiotics as these drugs are often developed for the treatment of multiple infectious disorders. In the case of antibiotics it is often known from preclinical studies that the compound will be efficacious against certain microbes.
As a result it is very likely that the compound will be efficacious in the range of infections caused by these bacteria, provided that the bacteria are exposed to therapeutic drug concentrations in the human body. For other types of compounds the applicability in different disorders could be less apparent, and the opportunity in new indications often appears only after launch of the compound.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
EMBALLAGE 2008. World Packaging Exhibition
16-21 November 2008, Paris-Nord Villepinte - France
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
 |
